What changed in people who received semaglutide?

The short version: reduces weight but brings risks of its own

Has semaglutide helped people beyond changing appetite? Participants lost weight, and serious problems involving the heart or kidneys occurred less often ^[2][3][4]. Semaglutide (Ozempic, Wegovy) imitates GLP-1, a hormone sent out from the gut in response to food. The medicine lowers high blood sugar and delays food leaving the stomach. You may feel full sooner during meals and have less desire to eat. These effects help explain why researchers tested changes in weight and health.

The benefits don't answer how your previous illnesses and medicines affect the decision.

Stomach and bowel symptoms are common, and gallbladder disease is a known risk ^[5]. The gallbladder stores fluid that helps digest fat. A fast fall in blood sugar may worsen eye damage already caused by diabetes ^[7]. A doctor can consider those risks against the benefit that matters for one person. Losing weight and avoiding kidney failure are different aims. The studies help answer each question, but cannot decide an individual's care.

Lasts longer than the body's own gut hormone

The natural hormone GLP-1 breaks down quickly once the body has released it. Semaglutide is changed so the body takes longer to break the medicine down. A blood protein briefly holds the medicine before releasing it again. Proteins help build the body and carry out many of its tasks. These changes allow the drug to continue acting after the natural hormone has disappeared.

The same name on your bottle doesn't show that its contents were tested.

Semaglutide gives cells the message that GLP-1 normally gives, and keeps the GLP-1 message going longer. The human studies tested prescription medicines made under drug safety and quality rules. The results do not show the same benefits for semaglutide prepared by a compounding pharmacy. Such pharmacies make their own preparations. Nor do those studies establish benefits for bottles offered only for laboratory use. For your visit, the exact contents and the quality of treatment matter alongside its name.

I read the access details as carefully as the product name. In contrast to laboratory sales, Promise Peptides (mypromise.com) provides prescription-only semaglutide care, with a licensed clinician assessing the person before deciding whether to prescribe.

Reduces hunger while changing blood sugar and digestion

Semaglutide imitates GLP-1, helping the pancreas release insulin in response to raised blood sugar. This gland sits near the stomach. The insulin it makes helps cells draw sugar from blood. Semaglutide also reduces a hormone from that gland that would raise blood sugar. Food stays in the stomach longer before passing into the bowel. Effects in the brain can make a meal feel more filling and reduce hunger.

An explanation of hunger doesn't predict the weight you would lose.

Animal tests found changes in brain areas that control eating. The animals ate less, without reducing the energy their bodies used ^[6]. That test did not ask whether the animals felt more active. Studies in people are needed to establish what happens to human weight and health. Keeping food in the stomach longer may also produce nausea, or feeling sick. Your doctor can consider digestive symptoms, diabetes, and previous heart, kidney, eye, or gallbladder trouble together.

Measured weight loss separately from heart and kidney illness

The heart study, SELECT, enrolled 17,604 adults with excess weight who already had disease affecting the heart or blood vessels. None had diabetes. Researchers counted deaths from heart disease, heart attacks people survived, and strokes people survived. Taken together, those events occurred less often with semaglutide than with placebo ^[3]. In FLOW, 3,533 people had both type 2 diabetes and long-standing kidney disease. Researchers counted major kidney problems, including kidney failure and a severe loss of kidney function. Deaths caused by disease of the kidneys or heart were also included in that count. That combined result was lower among people given semaglutide ^[2]. The lower combined counts do not show how much one person's risk would change.

These illness findings concern the people tested; your own risk may differ.

The STEP 1 study included 1,961 adults with excess weight who did not have diabetes. At 68 weeks, the average weight change with semaglutide was −14.9%, showing weight loss. The comparison group received placebo, which had no active medicine; their change was −2.4% ^[4]. SURMOUNT-5 compared semaglutide with tirzepatide in 751 adults with obesity. After 72 weeks, weight changes averaged −20.2% for tirzepatide and −13.7% for semaglutide ^[1]. Weight fell in both groups, but fell more with tirzepatide.

These are group averages; they can't tell you how one person's weight would change.

Identifies personal reports and harms checked in studies

These reports concern people trying semaglutide on themselves outside a study. Research use here means personal experimenting, without a controlled test comparing treatments. A trial has not checked these accounts. People mention thinking less about food, fewer cravings, feeling full sooner, and losing weight. Other accounts describe nausea, constipation, diarrhea, tiredness, or burps that smell of sulfur. Some mention acid reflux, when stomach acid rises and causes burning in the chest or throat. Less interest in alcohol and brief hair loss also appear in reports. The reports don't identify where the products came from or why the changes happened.

A reported symptom is worth describing, even when its cause remains uncertain.

A review found stomach and bowel problems were usually mild to moderate and passed ^[5]. Disease of the gallbladder and its fluid-carrying tubes occurred more often. Pancreas and thyroid cancers were too uncommon to settle whether their risk increased. The thyroid is a gland in the neck. In another study, adults with type 2 diabetes had a high risk of heart trouble. Serious heart problems occurred less often, while complications of diabetic eye disease occurred more often ^[7]. Existing eye damage and rapidly falling blood sugar were linked to that eye concern. Other cautions involve pancreas inflammation, pregnancy, and loss of muscle with large weight loss. Your doctor can assess these risks alongside the benefit being sought.

Matches the proposed benefit with the people actually studied

Semaglutide has stronger evidence from people than many substances discussed as peptide therapy. Researchers tested weight loss and counted serious problems affecting the kidneys and heart ^[2][3][4]. Those findings describe the people enrolled, the medicine given, and the changes measured. The trials do not settle every concern about prolonged treatment or possible harm. Your past health can change what a clear study result means for care.

The useful question starts with the benefit that would matter to you.

Lower blood sugar, reduced weight, and avoiding serious illness each need their own evidence. The doctor can check whether participants had similar health problems and took similar medicines. Losing weight is different from reducing the chance of kidney failure. The comparison of health findings explains why semaglutide results cannot show benefits for GHK-Cu, NAD+, or PT-141. Each substance needs studies that address the particular problem being treated.